Abstract
Polymeric lipid hybrid nanoparticles (PLNs) are core–shell nanoparticles made up of a polymeric kernel and lipid/lipid–PEG shells that have the physical stability and biocompatibility of both polymeric nanoparticles and liposomes. PLNs have emerged as a highly potent and promising nanocarrier for a variety of biomedical uses, including drug delivery and biomedical imaging, owing to recent developments in nanomedicine. In contrast with other forms of drug delivery systems, PLNs have been regarded as seamless and stable because they are simple to prepare and exhibit excellent stability. Natural, semi-synthetic, and synthetic polymers have been used to make these nanocarriers. Due to their small scale, PLNs can be used in a number of applications, including anticancer therapy, gene delivery, vaccine delivery, and bioimaging. These nanoparticles are also self-assembled in a reproducible and predictable manner using a single or two-step nanoprecipitation process, making them significantly scalable. All of these positive attributes therefore make PLNs an attractive nanocarrier to study. This review delves into the fundamentals and applications of PLNs as well as their formulation parameters, several drug delivery strategies, and recent advancements in clinical trials, giving a comprehensive insight into the pharmacokinetic and biopharmaceutical aspects of these hybrid nanoparticles.
Highlights
Introduction of LipidBased Drug Delivery SystemsNanotechnology is a plausible medical technology with the ability to significantly affect the distribution of a wide range of therapeutics, including genomes, peptides, small molecular RNA therapeutics, and medical imaging agents, as well as to enhance the pharmacokinetics and therapeutic index of many medicines systemically [1]
Polymeric lipid hybrid nanoparticles (PLNs) were first developed in the early 2000s to solve the issue of inserting ionic drugs into a hydrophobic stable lipid phase that are water-soluble in order to ensure sufficient loading and continuous release of active molecules [102]
PLNs may be used for a variety of applications, including anticancer therapy and bioimaging, due to their small size
Summary
Nanotechnology is a plausible medical technology with the ability to significantly affect the distribution of a wide range of therapeutics, including genomes, peptides, small molecular RNA therapeutics, and medical imaging agents, as well as to enhance the pharmacokinetics and therapeutic index of many medicines systemically [1]. A new generation of delivery systems, named polymeric lipid hybrid nanoparticles (PLNs) (Figure 1), was developed to take advantage of the special properties of polymeric nanoparticles and liposomes that contributed to their early therapeutic effectiveness, while addressing disadvantages such as their structural disintegration, shortened circulation period, and material leakage [23]. This hybrid system can be a sturdy drug delivery mechanism with excellent drug release kinetics, high encapsulation efficiency, and distinct drug uptake as well as appropriate tissue and molecular targets [24]. Polymeric lipid hybrid nanoparticles (PLNs) have the ability to improve the biocompatibility and physical stability of drugs, paving the way for their promising use in robust drug delivery
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
